A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia.

Drug Category: Array
Conference Category: Array
Lead Author: Mahadevan D, et al.
Published Date: 08/12/2015
Download Link: /wp-content/uploads/2019/03/TGR-Gazyva%20ASH%202015%20FINAL.PDF
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
astra-migrate-meta-layouts: set
stick-header-meta: default
Scroll to Top